DSP-6745

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally. The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 7 receptors. Its affinities (K i ) were 0.653 nM for the serotonin transporter (SERT), 0.331 nM for the serotonin 5-HT 2A receptor, 1.34 nM for the serotonin 5-HT 2C receptor, and 31.7 nM for the serotonin 5-HT 7 receptor.

Conversely, its or K b values were 0.753 nM at the SERT, 0.566 nM at the serotonin 5-HT 2A receptor, 1.37 nM at the serotonin 5-HT 2C receptor, and 2.12 nM at the serotonin 5-HT 7 receptor. It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT 2B receptor (K i = 7.58 nM). DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals. The chemical synthesis of DSP-6745 has been described. DSP-6745 was first described in the scientific literature by 2024.

It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma. The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.

DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally. The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 7 receptors. Its affinities (K i ) were 0.653 nM for the serotonin transporter (SERT), 0.331 nM for the serotonin 5-HT 2A receptor, 1.34 nM for the serotonin 5-HT 2C receptor, and 31.7 nM for the serotonin 5-HT 7 receptor.

Conversely, its or K b values were 0.753 nM at the SERT, 0.566 nM at the serotonin 5-HT 2A receptor, 1.37 nM at the serotonin 5-HT 2C receptor, and 2.12 nM at the serotonin 5-HT 7 receptor. It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT 2B receptor (K i = 7.58 nM). DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals. The chemical synthesis of DSP-6745 has been described. DSP-6745 was first described in the scientific literature by 2024.

It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma. The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370057179 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.